Légeret Corinne, Furlano Raoul, Köhler Henrik
University Children's Hospital of Basel, 4056 Basel, Switzerland.
Children's Hospital Kantonsspital Aarau, 5000 Aarau, Switzerland.
Children (Basel). 2022 Apr 26;9(5):617. doi: 10.3390/children9050617.
The incidence of inflammatory bowel disease (IBD) is increasing, and more children at a younger age are affected. The pathogenesis seems to be an interaction of microbial factors, a sensitivity of the immune system, and the intestinal barrier, leading to an inappropriate immune response. Not only has the role of biological agents become more important in the last decade in the treatment of children and adolescents, but also new insights into the composition of the gastrointestinal microbiome and personal diet implications have increased our understanding of the disease and opened up potential therapeutic pathways. This narrative review provides an overview of current recommendations, therapeutic options, drug monitoring, and practical guidelines for paediatricians involved with paediatric IBD patients. Furthermore, the off-label use of potential helpful drugs in the treatment of these patients is discussed.
炎症性肠病（IBD）的发病率正在上升，越来越多的低龄儿童受到影响。其发病机制似乎是微生物因素、免疫系统敏感性和肠道屏障之间的相互作用，导致不适当的免疫反应。在过去十年中，生物制剂在儿童和青少年治疗中的作用不仅变得更加重要，而且对胃肠道微生物群组成和个人饮食影响的新认识也加深了我们对该疾病的理解，并开辟了潜在的治疗途径。这篇叙述性综述概述了针对儿科IBD患者的儿科医生的当前建议、治疗选择、药物监测和实用指南。此外，还讨论了在这些患者治疗中潜在有用药物的超说明书使用情况。
